Dihexa for Cognitive Enhancement
Evidence Review created on 10/30/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: PNB-0408, ATH-1001, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, Dihexa acetate
Motivation
Dihexa is a small laboratory-made molecule built from a fragment of a hormone best known for regulating blood pressure. It was designed to survive digestion and enter the brain, where it is proposed to strengthen a natural growth signal that helps nerve cells form new connections. That idea of rebuilding brain wiring, rather than only slowing its loss, is what draws interest from people seeking sharper memory and thinking as they age.
The compound emerged from university dementia research in the 2000s, and its inventors described its potency in strikingly strong terms. A company was founded to develop it and later moved its human testing to a related molecule, while an investigation into image manipulation in early papers reshaped how the original research is read. Dihexa itself is not an approved medicine but is sold online as a research chemical.
This review examines dihexa for cognitive enhancement in health-focused adults: the animal and laboratory evidence, the human trials of its closest relative, the safety questions raised by a growth-promoting mechanism, the reliability of the research record, its regulatory status, and the practical considerations surrounding its use.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
These items give a high-level view of dihexa’s proposed mechanism and the independent animal studies that tested it.
-
The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer’s Disease - Wright & Harding, 2015
The inventors’ narrative review of how dihexa is proposed to boost hepatocyte growth factor (HGF, a tissue-repair protein) signaling through its receptor c-Met (also written MET); both authors co-founded the company commercializing it.
-
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway - Sun et al., 2021
An independent study testing this AngIV (angiotensin IV, a hormone fragment) analog in APP/PS1 mice (bred to develop Alzheimer’s-like plaques) and linking effects to PI3K/AKT (a cell-survival pathway).
-
Hepatocyte Growth Factor/MET Activator Rescues Working Memory Deficits after Repeated Mild Traumatic Brain Injury - Martino et al., 2025
An independent rat study in which dihexa restored working memory after repeated mild brain injury and a MET-blocking peptide abolished the effect, directly testing the proposed HGF/MET mechanism.
-
Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats - Wells et al., 2024
An independent rat study finding dihexa did not protect against motor or memory deficits in a toxin model of Huntington’s disease (an inherited brain-degenerating disorder), a null result limiting generalization.
Only four items are listed: the developer’s fosgonimeton trial and further inventor material would duplicate the first item’s company source, and an Alzheimer’s Drug Discovery Foundation evidence report on dihexa is available only as a PDF.
No dihexa content was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; web and on-site searches returned nothing on the compound, which has never been tested directly in a human trial.
Grokipedia
-
A broad AI-written overview of dihexa’s chemistry, animal findings and development history; it repeats a binding figure from a since-retracted paper without flagging the retraction.
Examine
No Examine article on dihexa exists. Examine focuses on supplements and nutrition, and dihexa is an unapproved experimental compound rather than a dietary supplement.
ConsumerLab
No ConsumerLab article on dihexa exists. ConsumerLab tests commercially sold supplements and has not reviewed this experimental research compound.
Systematic Reviews
One systematic review covers dihexa, within the angiotensin IV family (fragments of the blood-pressure hormone angiotensin).
-
Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies - Ho & Nation, 2018
Animal-only review of 32 studies; eight of nine cognitive-deficit studies found angiotensin IV or analogs, including dihexa, improved memory tasks.
No systematic review or meta-analysis addresses dihexa’s principal risk, tumor promotion through HGF/MET activation; that side of the trade-off is unrepresented.
Mechanism of Action
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a capped three-amino-acid fragment of angiotensin IV, a breakdown product of angiotensin II in the renin–angiotensin system (the hormone cascade regulating blood pressure). The caps were added to resist digestion and cross the blood–brain barrier (McCoy 2013, by the inventors, who hold a financial stake; it carries a McCoy 2013 notice of concern). Fosgonimeton, the developer’s injectable drug, is a prodrug the body converts into dihexa (Athira press release).
- Proposed primary mechanism: Dihexa reportedly binds HGF and helps it activate MET, triggering growth of dendritic spines (small protrusions where synapses form) and synapses (connections between nerve cells). The paper establishing this was retracted for falsified or fabricated data (Benoist 2014 retraction notice); an independent rat study found that a MET-blocking peptide abolished dihexa’s memory effect (Martino 2025).
- Downstream signaling: In Alzheimer’s-model mice, dihexa activated PI3K/AKT and lowered inflammatory messengers (Sun 2021).
- Competing explanation: Angiotensin IV binds the AT4 site, identified as insulin-regulated aminopeptidase (IRAP, an enzyme that breaks down memory-related neuropeptides) (Albiston 2001); whether dihexa acts through IRAP, MET or both is unresolved.
- Pharmacology: The rat half-life was 12.68 days after intravenous dosing, with extensive tissue uptake (McCoy 2013). In a company-funded fosgonimeton trial, the active breakdown product’s plasma half-life was about 1.5 hours, without accumulation (Hua 2022); oral human data are lacking. Rat liver tests showed very low first-step metabolism by CYP enzymes (cytochrome P450, the main drug-processing liver enzymes) (McCoy 2013); human metabolism and selectivity are uncharacterized.
Historical Context & Evolution
- Original intended use: From 1992, Washington State University researchers Joseph Harding and Jay Wright studied angiotensin IV’s memory effects; around 2007 Harding designed dihexa as an oral, brain-penetrant version intended to treat dementia, including Alzheimer’s disease (WSU Insider announcement).
- Path to health optimization: The 2012 announcement claimed dihexa formed new synapses seven orders of magnitude more potently than brain-derived neurotrophic factor (BDNF, a nerve-growth protein) in cell assays. That claim, oral activity and online “research chemical” availability drew people pursuing cognitive enhancement.
- Commercial path: M3 Biotechnology, founded to commercialize dihexa, became Athira Pharma in 2019 and moved human testing to fosgonimeton (Alzforum fosgonimeton entry).
- Research-integrity reckoning: In 2021 the journal flagged four founding papers (Retraction Watch report); in 2025 it retracted three (Kawas 2011 retraction notice, Kawas 2012 retraction notice), including the mechanism paper, whose falsified or fabricated data Leen Kawas, the company’s former chief executive, and Joseph Harding were found solely responsible for (Benoist 2014 retraction notice). Athira agreed to pay $4,068,698 to settle allegations that it failed to report misconduct allegations to the National Institutes of Health (US Department of Justice release).
- Current standing: The rat-memory paper (McCoy 2013) remains unretracted under concern. The large company-funded fosgonimeton trial found no significant cognitive benefit (Porsteinsson 2025), while independent animal studies were positive after brain injury (Martino 2025) and negative in a model of Huntington’s disease (an inherited brain-degenerating disorder) (Wells 2024). The mechanism remains an open question, not a settled one.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no controlled human trial of dihexa itself exists, and the only human trials tested its injectable prodrug in people with dementia.
Medium 🟩 🟩
No benefit reaches Medium: the only human outcome data come from trials of its injectable prodrug, which are indirect evidence; dihexa itself has only cell and animal data.
Low 🟩
Memory and Cognition ⚠️ Conflicted
Dihexa restored memory in impaired rodents (McCoy 2013, Sun 2021, Martino 2025), not Huntington’s-model rats (Wells 2024). The prodrug fosgonimeton (indirect: form, route, population) showed no significant benefit in Alzheimer’s (Porsteinsson 2025) and missed primary endpoints in ACT-AD and SHAPE (Alzforum fosgonimeton entry). Net, no human cognitive benefit is shown.
Magnitude: In LIFT-AD, the ADAS-Cog11 (Alzheimer’s Disease Assessment Scale–Cognitive Subscale, a 70-point test where lower is better) improved 0.70 points more than placebo at 26 weeks (standard error, a measure of how precise the estimate is, 0.77; p = 0.35, where the p-value is the probability of a difference this large by chance alone; not significant; no 95% confidence interval, the range likely to contain the true effect, reported) (Porsteinsson 2025).
Speculative 🟨
Synapse Formation
In cultured rat neurons and brain slices, dihexa increased dendritic spines and synapses at picomolar (trillionth-molar) concentrations (McCoy 2013). Evidence is laboratory only, and the main follow-up study was retracted.
Reduced Brain Inflammation
In Alzheimer’s-model mice, dihexa reduced activation of brain immune cells, lowered inflammatory messengers and raised an anti-inflammatory one (Sun 2021). Evidence is a single mouse study.
Benefit-Modifying Factors
- Genetic variants: No gene variant is known to alter response to dihexa. In the null fosgonimeton trial, prespecified subgroups showed a larger difference from placebo in carriers of APOE4 (an APOE cholesterol-transport gene variant raising Alzheimer’s risk) than in non-carriers (Porsteinsson 2025).
- Baseline cognition: Animal benefits appeared only in impaired animals. The inventors noted that their unscreened aged rats included normal learners (McCoy 2013), so people without deficits may have little room to improve.
- Baseline biomarkers: No baseline blood or imaging marker is known to predict response, and HGF levels are not part of routine testing.
- Sex: A rat brain-injury study found no sex-dependent differences in memory performance and pooled sexes (Martino 2025); no human data exist for dihexa.
- Pre-existing conditions: Fosgonimeton’s effects appeared to differ in users of cholinesterase inhibitors (Alzheimer’s drugs that slow acetylcholine breakdown, such as donepezil), so its pivotal trial stopped enrolling them (Porsteinsson 2025). Brains with neuron loss may respond differently than healthy ones.
- Age: 24-month-old rats improved on oral dihexa (McCoy 2013), whereas fosgonimeton recipients averaging 73 years showed no significant benefit (Porsteinsson 2025). Older adults also carry higher baseline cancer risk, relevant to the growth-signal mechanism.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: dihexa itself has never been given directly in a registered human trial, and all controlled human safety data come from trials of its injected prodrug by a single sponsor.
Medium 🟥 🟥
No risk reaches Medium: the only controlled human safety data concern fosgonimeton, an injected prodrug of dihexa, whose different form and route cap them at Low as indirect evidence.
Low 🟥
Injection-Site Reactions
Daily under-the-skin injections of fosgonimeton, an injected prodrug of dihexa, caused mostly mild-to-moderate injection-site reactions, the main reason for adverse-event discontinuations in LIFT-AD (Porsteinsson 2025). Evidence is indirect (prodrug form, injected route); it bears mainly on injected products.
Magnitude: 57.1% (40 mg) and 72.9% (70 mg) versus 14.2% on placebo over 26 weeks; discontinuation for adverse events 10.7% and 21.5% versus 4.6% on placebo (Porsteinsson 2025); 17 of 27 (40 mg) and 21 of 26 (70 mg) versus 1 of 24 on placebo in the smaller ACT-AD trial (NCT04491006); 2 of 9 (40 mg) and 4 of 10 (70 mg) versus 0 of 9 on placebo in the SHAPE dementia trial (NCT04831281).
Eosinophilia
Eosinophilia (raised eosinophils, allergy-related white blood cells) occurred with fosgonimeton; it was transient, symptom-free and reversible, mostly accompanying injection-site reactions (Porsteinsson 2025). Evidence is indirect (prodrug form and injected route); oral dihexa is untested.
Magnitude: 7.1% (40 mg) and 7.5% (70 mg) versus 0% on placebo in LIFT-AD (Porsteinsson 2025); 6 of 27 and 5 of 26 versus 1 of 24 on placebo in the smaller ACT-AD trial (NCT04491006).
Angioedema
Angioedema (sudden swelling of deep skin layers, sometimes of the face or throat) occurred as a serious adverse event suspected to be related to fosgonimeton in LIFT-AD (Porsteinsson 2025). Evidence is indirect (prodrug form and injected route); oral dihexa is untested.
Magnitude: Serious angioedema in 2 of 331 fosgonimeton recipients (1 of 224 at 40 mg, 1 of 107 at 70 mg) versus 0 of 218 on placebo over 26 weeks (Porsteinsson 2025).
Other Suspected Drug-Related Serious Events
Besides angioedema, three serious adverse events in LIFT-AD were suspected to be related to fosgonimeton: fecaloma (hardened stool blocking the bowel), fever and diarrhea (Porsteinsson 2025). Each occurred once. Evidence is indirect (prodrug form, injected route); oral dihexa is untested.
Magnitude: Fecaloma and fever, one each among 224 recipients at 40 mg, and diarrhea in 1 of 107 at 70 mg, versus none of 218 on placebo over 26 weeks (Porsteinsson 2025).
Tumor Growth Promotion
HGF/MET signaling drives growth, survival and spread of many cancers, per a review (Comoglio 2018). Dihexa increased a cell-migration marker in canine kidney cells (Martino 2025). Four participants in an uncontrolled extension of injected fosgonimeton developed serious cancers (NCT04886063). Evidence is indirect (prodrug) and uncontrolled; no carcinogenicity study exists.
Magnitude: Serious cancers (colon, kidney, lung, prostate) in 4 of 423 participants over up to 173 weeks of open-label fosgonimeton (no control group), so no comparison with background incidence is possible (NCT04886063).
Long-Term Toxicity
Long-term growth-factor signaling could cause organ toxicity. The Food and Drug Administration (FDA) found no human exposure data on dihexa acetate products (FDA bulk-substance safety page). Controlled prodrug data span 26 weeks (Porsteinsson 2025); an uncontrolled fosgonimeton extension ran up to 173 weeks (NCT04886063). Evidence is indirect (prodrug, injected route).
Magnitude: Over up to 173 weeks of open-label fosgonimeton, 54 of 423 participants had serious adverse events and 4 died (no control group), so no excess attributable to the drug can be derived (NCT04886063).
Speculative 🟨
No risk rests on laboratory or animal evidence alone: every listed risk has at least uncontrolled human data from the injected prodrug.
Risk-Modifying Factors
- Genetic variants: Inherited activating MET mutations cause hereditary papillary renal carcinoma (an inherited kidney cancer) (Schmidt 1997); carriers face a theoretically larger tumor-promotion risk. No drug-processing gene variants have been studied for dihexa.
- Baseline biomarkers: An already elevated eosinophil count makes the eosinophilia seen with fosgonimeton harder to interpret, and abnormal cancer-screening results raise the stakes of the growth-signal mechanism.
- Sex: No sex-specific risk data exist for dihexa; fosgonimeton showed no sex difference in blood levels (Hua 2022).
- Pre-existing conditions: Active or past cancer and precancerous lesions carry the main theoretical risk; liver or kidney disease adds uncertainty because dihexa’s elimination route is unknown; allergic or eosinophilic disorders complicate blood-count interpretation.
- Age: Cancer incidence rises with age, so older users more often harbor undetected tumors that growth-factor signaling could theoretically accelerate; fosgonimeton safety data come from participants averaging 73 years (Porsteinsson 2025).
Key Interactions & Contraindications
Documented interactions:
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): In prodrug fosgonimeton trials, prespecified comparisons suggested these drugs blunted its effects, so LIFT-AD stopped enrolling their users (Porsteinsson 2025); the developer reported antagonism of HGF/MET signaling (Alzforum fosgonimeton entry). Mitigation: judging response only on a stable regimen.
Theoretical interactions (inferred from mechanism, not studied in humans):
- MET-targeted cancer drugs (capmatinib, tepotinib, crizotinib, cabozantinib): Avoid. Opposing action at the MET receptor could blunt their anticancer effect. Mitigation: no dihexa use during MET-targeted therapy.
- EGFR inhibitors (drugs blocking the epidermal growth factor receptor in lung cancer, such as osimertinib, erlotinib): MET activation is a recognized escape route from such drugs, per a review (Comoglio 2018), so dihexa could theoretically foster resistance. Mitigation: no use during cancer therapy.
- Anticholinergic drugs (drugs that block the memory messenger acetylcholine), including over-the-counter sleep aids and antihistamines (diphenhydramine, doxylamine) and bladder drugs (oxybutynin): This blockade impairs memory, the same action scopolamine uses to impair rats in dihexa studies, opposing the cognitive aim. Mitigation: minimizing regular use.
- Renin–angiotensin drugs (ACE inhibitors, which block angiotensin II formation, such as lisinopril; angiotensin receptor blockers, which block its action, such as losartan): Dihexa derives from angiotensin IV; its human blood-pressure effects are unstudied, so pressure may shift unpredictably. Mitigation: home blood-pressure checks early on.
- Growth-promoting agents (somatropin, tesamorelin, ibutamoren): Additive growth-factor signaling could compound the theoretical tumor-promotion risk. Mitigation: avoiding combined use.
- Neurotrophic (nerve-growth-promoting) supplements and peptides (lion’s mane (Hericium erinaceus), Semax): Additive nerve-growth signaling with an unknown combined effect, including possible overstimulation. Mitigation: introducing one agent at a time so effects can be attributed.
- Alcohol: Alcohol impairs memory consolidation in the hippocampus (the brain’s memory center), working against the cognitive aim and confounding self-assessment. Mitigation: avoiding intake around cognitive testing.
Populations who should avoid Dihexa:
- Active or past cancer, or known precancerous lesions: inferred from HGF/MET’s role in tumor growth and spread, per a review (Comoglio 2018); no human data.
- Carriers of activating MET mutations (hereditary papillary renal carcinoma): inferred from MET-driven tumor formation (Schmidt 1997); no human data.
- Pregnancy and breastfeeding: FDA identified no human exposure data on dihexa acetate products (FDA bulk-substance safety page); inferred from HGF’s essential role in placental development in mice (Uehara 1995); no human data.
- People under 18: inferred from HGF/MET’s role in tissue growth and development, which is still ongoing in the brain and body; no human data.
- People receiving MET-targeted or EGFR-targeted cancer therapy: inferred from opposing action at MET and MET-driven drug resistance, per a review (Comoglio 2018); no human data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Cancer screening beforehand: Completing age-appropriate cancer screening before starting lowers the chance of exposing an undetected tumor to amplified growth-factor signaling (tumor promotion).
- Eosinophil checks: A complete blood count at baseline and 4 weeks, stopping if eosinophils reach 1,500 cells/µL, the hypereosinophilia threshold (Valent 2012), guards against the eosinophilia seen with fosgonimeton.
- Avoiding injectable forms: Oral use avoids the injection-site reactions that affected most fosgonimeton recipients (Porsteinsson 2025) and the infection risk of unregulated, possibly non-sterile injectables.
- Short, defined trial period: A planned 4–8 week trial with a fixed stop date limits exposure to unknown long-term toxicity and tumor promotion, given controlled human prodrug safety data of at most 26 weeks (Porsteinsson 2025).
- Verified product: Independent laboratory confirmation of identity and purity reduces the risk of contaminated, mislabeled or substituted material from unregulated vendors.
- One change at a time: Starting no other new cognitive enhancer, peptide or medication for 4 weeks allows any adverse effect to be attributed and avoids additive interactions.
- Warning-sign stop rule: New lumps, unexplained weight loss, persistent cough, or blood in urine or stool prompt stopping and medical evaluation, addressing possible tumor promotion.
Therapeutic Protocol
Other parameters without a citation (timing, frequency, duration, titration) reflect common practice; no clinical guideline, label or trial regimen exists for dihexa.
- No established human dose: No trial has given dihexa itself to people, and FDA found no human exposure data on dihexa acetate products (FDA bulk-substance safety page); every dose in use is extrapolated or self-selected.
- Animal-derived estimate: Rats received 2 mg/kg/day orally (McCoy 2013); body-surface-area conversion per a dose-conversion guide (Nair 2016), dividing the rat dose by 6.2, gives about 0.32 mg/kg, roughly 22 mg for a 70 kg adult.
- Safety-margin caveat: FDA’s first-in-human method divides a no-adverse-effect animal dose by at least 10 (FDA dose-estimation guidance); no such dose is published for dihexa, so the conversion above is not safety-adjusted.
- Competing approaches: The inventors popularized oral use (WSU Insider announcement); vendors and online communities circulate oral, skin-applied and injected regimens without published sources. No clinic or practitioner has published a protocol.
- Prodrug regimen: Fosgonimeton, an injected prodrug of dihexa, was given at 40 mg daily (Porsteinsson 2025); this does not transfer directly to oral dihexa, whose absorption in people is unstudied.
- Time of day: Morning use is common practice because some users report stimulation; no study has compared dosing times.
- Half-life: The rat elimination half-life was 12.68 days (McCoy 2013); in people injected with fosgonimeton, the active breakdown product’s plasma half-life was about 1.5 hours, without accumulation (Hua 2022). The oral human half-life is unknown.
- Single or split dosing: Human prodrug data show plasma clearance within 24 hours (Hua 2022), unlike the multi-day rat value; no study has compared single and split oral dosing, and single daily doses are common practice.
- Genetic variants: No data exist on gene variants affecting dihexa response; carriers of activating MET mutations face added theoretical tumor risk, and APOE4’s influence on response is unknown.
- Sex: No data show sex differences in dosing or response; fosgonimeton blood levels did not differ by sex (Hua 2022).
- Age: Aged rats improved at 2 mg/kg/day (McCoy 2013); older adults carry higher baseline cancer risk, which weighs on any dose choice.
- Baseline biomarkers: Baseline cognitive scores set the room for improvement; abnormal eosinophil, liver or kidney results at baseline weigh against starting.
- Pre-existing conditions: A cancer history excludes use; cholinesterase-inhibitor users may experience a blunted effect, as suspected with fosgonimeton (Porsteinsson 2025).
Discontinuation & Cycling
- Short-term, not lifelong: With no long-term safety data, dihexa is used as a time-limited trial with a planned stop date, not as lifelong therapy.
- Withdrawal effects: No withdrawal effects have been documented; no human data exist on stopping.
- Tapering: No taper protocol exists; human prodrug data show plasma clearance within 24 hours (Hua 2022), so blood levels likely fall quickly after stopping, though oral dosing is unstudied.
- Cycling: No evidence shows cycling maintains efficacy; on-off cycles used by self-experimenters are untested, though breaks limit cumulative exposure.
- Stopping triggers: A new cancer diagnosis or warning signs, eosinophils of 1,500 cells/µL or more, or no measurable cognitive change by the planned end date.
Sourcing and Quality
- No approved or compounded source: Dihexa is not FDA-approved and is not on the list of substances pharmacies may compound; FDA is still considering it for that list (FDA advisory committee page), so supply comes only from “research use only” vendors.
- Identity and purity testing: A certificate of analysis from an independent laboratory, using high-performance liquid chromatography (a purity test) and mass spectrometry confirming a molecular weight near 504.7 (C₂₇H₄₄N₄O₅), verifies the product.
- Salt form: Dihexa acetate, the form nominated to FDA (FDA bulk-substance safety page), weighs more per milligram of active molecule than the free base; labels often do not state which is supplied.
- Formulation risks: Injectables need sterility and endotoxin (bacterial toxin) testing; skin absorption is unstudied; oral activity has been shown only in rats.
- Reputable brands: No vendor or compounding pharmacy can be identified as reputable through independent testing; ConsumerLab and similar testers have not evaluated dihexa products.
Practical Considerations
- Time to effect: Rats improved within an 8-day maze-training period (McCoy 2013); fosgonimeton altered brain-wave recordings within 9 days (Hua 2022). The human time course for dihexa is unknown.
- Common pitfalls: Treating rat results and press-release potency claims as human evidence, overlooking the retractions, buying untested products, combining several cognitive enhancers, and judging effects without baseline testing.
- Regulatory status: Dihexa is not FDA-approved: FDA has identified no human exposure data on any dihexa acetate drug product, and its significant-safety-risk compounding nomination was withdrawn (FDA bulk-substance safety page); an advisory committee review is due before March 2027 (FDA advisory committee page).
- Cost and access: Dihexa is not on the list of substances pharmacies may compound (FDA advisory committee page) and no insurer covers it, so no payer holds a financial stake in its adoption or rejection; access depends on unregulated vendors.
- Conflicts of interest: Most dihexa data come from inventors who co-founded its developer, and all human data on related compounds come from company-funded trials.
Interaction with Foundational Habits
- Sleep: Direction: none documented. No study has measured dihexa’s effect on sleep; reports of stimulation are anecdotal. Because memory consolidation depends on sleep, any sleep disruption would offset the cognitive aim; morning use is common practice, and sleep tracking can reveal changes.
- Nutrition: Direction: none known. No food-effect, absorption or nutrient-depletion study exists, and oral activity is shown only in rats (McCoy 2013). Its fat-soluble design suggests absorption may vary with meals, so consistent timing relative to food keeps self-testing comparable.
- Exercise: Direction: none documented; any overlap is untested. Aerobic exercise independently raises brain growth factors such as BDNF and supports memory; whether dihexa adds to, mimics or blunts that effect is unknown. Keeping training routines stable during a trial keeps self-assessment interpretable.
- Stress management: Direction: none documented. No data exist on cortisol (the main stress hormone) or stress responses. Chronic stress impairs the memory networks dihexa is meant to support, so unmanaged stress would confound perceived benefit; meditation and similar practices have no known interaction.
Monitoring Protocol & Defining Success
Baseline: Before starting, baseline testing covers a complete blood count (CBC) with eosinophils, the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), serum creatinine, home blood pressure, and two cognitive baselines using the Montreal Cognitive Assessment (MoCA) or a computerized battery. Age-appropriate cancer screening is completed beforehand.
Ongoing: Tests are repeated at 4 weeks, at the planned trial end (commonly 8 weeks), then every 3 months if use continues, with cognitive testing at the same time of day and under similar sleep conditions. Success is defined in advance as improvement exceeding the individual’s baseline variability, with no eosinophil, liver or kidney abnormality.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Eosinophil count (CBC) | 0–500 cells/µL (standard reference range) | Safety check: rose with a related compound | Non-fasting. Stop at 1,500 cells/µL, the hypereosinophilia threshold (Valent 2012); seen in about 7% on fosgonimeton (Porsteinsson 2025) |
| ALT and AST | ALT 7–56 U/L; AST 10–40 U/L (standard reference range) | Safety check: human liver effects unknown | Non-fasting; ranges vary by laboratory; avoid intense exercise 48 hours before testing, which can raise AST |
| Serum creatinine | 0.6–1.3 mg/dL (standard reference range) | Safety check: elimination route unknown | Non-fasting; pair with estimated glomerular filtration rate (eGFR, a kidney-function estimate); ranges vary by sex and laboratory |
| Cognitive test score (MoCA or computerized battery) | No established target; track change from own baseline | Marker expected to change | MoCA flags impairment below 26 (Nasreddine 2005) but has a ceiling in healthy adults; computerized batteries detect smaller changes; test at the same time of day |
Qualitative markers:
- Recall of names and recent events
- Focus during demanding work
- Sleep quality
- Mood or anxiety
- Headache frequency
- Skin changes at application sites
- New lumps or unexplained weight loss
Emerging Research
- No dihexa trials registered: A ClinicalTrials.gov search on 10/30/2026 found no study of dihexa or PNB-0408; all human data concern its injectable prodrug or related compounds. A first dihexa trial, positive or null, would replace inference with direct evidence.
- LIFT-AD, completed 2024: Phase 2/3 fosgonimeton trial in mild-to-moderate Alzheimer’s disease (NCT04488419), 554 enrolled, primary endpoint a combined cognition-and-function score. Published results showed no significant benefit (Porsteinsson 2025), cited under Expected Benefits.
- ACT-AD, completed 2022: Phase 2 fosgonimeton trial (NCT04491006), 77 participants, primary endpoint P300 latency (a brain-wave timing marker of processing speed). The developer reported the primary endpoint was missed (Alzforum fosgonimeton entry); its eosinophilia data are cited under Risks.
- SHAPE, terminated 2023: Phase 2 fosgonimeton trial (NCT04831281) in Parkinson’s disease dementia or dementia with Lewy bodies (dementia driven by abnormal protein deposits), stopped at 28 of 75 planned participants; the primary endpoint was missed (Alzforum fosgonimeton entry).
- ATH-1105, completed 2024: Phase 1 safety study of an oral HGF/MET modulator in 80 healthy volunteers (NCT06432647). No registry results are posted; the developer reported favorable safety, tolerability and blood levels rising in proportion to dose (Athira ATH-1105 press release). This supports oral HGF/MET modulation but does not test dihexa itself.
- FDA advisory review: FDA’s Pharmacy Compounding Advisory Committee will discuss dihexa acetate before March 2027 (FDA advisory committee page). A favorable outcome could open pharmacy compounding; an unfavorable one keeps dihexa outside legal supply.
- Independent replication: A MET-dependent memory rescue after brain injury (Martino 2025) strengthens the mechanism, while a null Huntington’s-model study (Wells 2024) weakens generalization; healthy aged animals remain untested.
- Cancer-safety gap: No published carcinogenicity or long-term toxicology study of dihexa exists; the developer reports unpublished long-term animal toxicology of its prodrug (Athira press release). MET’s role in tumor progression, summarized in a review (Comoglio 2018), makes such data the key missing piece for weighing long-term use.
Conclusion
Dihexa is a laboratory-made fragment of a blood-pressure hormone, engineered to reach the brain and proposed to strengthen a natural growth signal that helps nerve cells build new connections. For health-focused adults seeking sharper memory with age, its appeal rests on the idea of rebuilding brain wiring rather than only protecting it.
The evidence behind that appeal is thin. Every finding for dihexa itself comes from cells and animals, mostly from its inventors, who also founded the company built around it. The journal withdrew three of their key papers for falsified or fabricated data, and a fourth carries a formal warning. Independent animal studies point in both directions. No study has tested dihexa’s effect on memory in healthy animals or people, and the large human trial of an injectable drug that the body converts into dihexa found no meaningful memory benefit in Alzheimer’s disease.
The safety picture is mostly unknown rather than reassuring. The growth signal dihexa is meant to boost also helps many cancers grow and spread, making tumor promotion the central theoretical concern, especially with age. The related drug frequently caused skin reactions where injected and occasional rises in allergy-related white blood cells. Dihexa lingers for days in rats but cleared within a day in people given the injectable form, has no published long-term animal safety testing, and reaches users only through unregulated sellers.
Overall, dihexa is an experimental compound whose benefits for thinking in people are undemonstrated and whose risks remain largely uncharacterized.